Does a single dose of medication delivered directly to your bladder reduce the chance of cancer returning? Intravesical chemotherapy delivers cancer-fighting medicines directly into the bladder through a catheter (a thin, flexible tube), targeting residual cancer cells that may remain after tumour removal. This localised approach concentrates treatment where it’s needed and minimises systemic side effects that occur with intravenous chemotherapy.
For patients with non-muscle-invasive bladder cancer (cancer that hasn’t grown into the bladder’s muscle layer), intravesical therapy may help reduce the return of tumours that would otherwise require repeated surgical interventions. The bladder’s anatomy makes it suited to this treatment approach. Unlike most organs, the bladder can retain fluid for extended periods, allowing chemotherapy agents to maintain prolonged contact with the urothelial lining or the inner surface of the bladder, where superficial cancers develop.
How Intravesical Chemotherapy Works
The treatment mechanism relies on several pharmacological principles working together:
- Chemotherapy agents penetrate the bladder wall’s superficial layers where non-muscle-invasive cancers reside
- They damage DNA in rapidly dividing cancer cells and trigger cell death
- The urothelium’s limited blood supply means minimal drug absorption into the bloodstream, keeping systemic exposure low
Mitomycin C is a commonly used intravesical chemotherapy agent. This antibiotic-derived compound cross-links DNA strands (binds DNA together), preventing cancer cells from replicating. Its significant molecular size limits absorption through the bladder wall, making it suitable for localised delivery. The drug works when instilled shortly after transurethral resection (a procedure in which the surgeon removes the tumour through the urethra). This timing prevents any cells dislodged during surgery from implanting elsewhere in the bladder.
Gemcitabine represents a newer option gaining clinical acceptance. This nucleoside analogue, a synthetic compound that mimics building blocks of DNA, incorporates into DNA during replication. It causes strand breaks and cell death.
Treatment Protocols and Timing
Single immediate post-operative instillation may reduce recurrence in patients with low-risk tumours. Urologists (doctors who specialise in urinary system conditions) typically administer the chemotherapy within a few hours of surgery, when residual cancer cells may be vulnerable. This timing addresses the period before floating tumour cells can attach to the bladder wall and establish new growth sites.
Induction therapy for intermediate-risk patients involves weekly instillations over several weeks. Each session delivers a fresh dose of chemotherapy, maintaining consistent pressure on residual microscopic disease. The weekly schedule allows the bladder lining to recover between treatments while addressing cancer cells.
Maintenance protocols extend treatment for months or years in patients at higher risk of recurrence. Your doctor will set the treatment schedule based on your specific risk factors, including tumour characteristics and response to initial treatment. Schedules vary, but monthly instillations for the first year, followed by periodic therapies, are a common approach. This extended exposure aims to address cancer cells that may have remained dormant during initial treatment or developed from pre-cancerous changes in the bladder lining.
What Happens During Treatment
The procedure follows a precise sequence:
- Catheter insertion: A healthcare provider inserts a catheter into the bladder through the urethra (the tube that carries urine out of the body). This thin, flexible tube allows complete drainage of urine before chemotherapy instillation. The process takes only a few minutes. You may feel pressure or slight discomfort, but it should not be painful.
- Chemotherapy instillation: Chemotherapy solution flows through the catheter into the empty bladder, typically an appropriate volume depending on the agent used. The catheter is then removed.
- Medication retention: Patients retain the medication for a specified dwell time, usually one to two hours. During this period, patients change position periodically, lying on their sides, backs, and stomachs, to ensure the solution contacts all bladder surfaces.
- Voiding: After the dwell time, patients void the medication into the toilet. Flush twice and wash hands thoroughly to prevent exposure to household members. Men should sit while urinating for the first few voids after treatment to minimise splashing. These precautions continue for several hours post-treatment.
💡 Did You Know?
The bladder can safely hold chemotherapy solutions at concentrations that would cause toxicity if delivered intravenously, making intravesical therapy a localised treatment approach.
Managing Side Effects
Bladder irritation represents the most frequent side effect. Symptoms include:
- Urinary frequency or needing to urinate often
- Urgency, or the feeling of a sudden, strong need to urinate
- Burning during urination
- Mild blood in the urine
These effects typically peak during the treatment course. They resolve within weeks of completing therapy.
Skin reactions on the hands, particularly with mitomycin C, can occur if medication contacts skin during voiding. Wash the genital area after urination. Avoid touching eyes or face before handwashing to prevent chemical irritation. Patients who develop palm rashes or peeling should inform their urologist, as this may indicate sensitivity requiring protocol modification.
Reduced bladder capacity develops in some patients receiving extended maintenance therapy. Repeated chemical exposure can cause bladder wall scarring and decreased elasticity. Symptoms include needing to urinate more frequently with smaller volumes. Cases may require treatment modification.
⚠️ Important Note
Contact your urologist promptly if you develop fever, severe pain, or inability to urinate after treatment, as these symptoms may indicate infection or bladder spasm requiring medical attention.
Factors Affecting Treatment Success
Tumour characteristics influence outcomes. Low-grade (slower-growing, less aggressive), small, solitary tumours may respond differently from high-grade (faster-growing, more aggressive), large, or multiple tumours. Tumours that haven’t invaded the lamina propria (the layer beneath the bladder’s inner surface), classified as stage Ta, carry different prognoses than those penetrating this layer (stage T1). These factors guide urologists in selecting appropriate treatment intensity.
Complete tumour resection before chemotherapy is essential for treatment effectiveness. Intravesical agents work differently against microscopic disease (cancer cells too small to see) compared to visible tumours. The surgeon achieves clear margins (removes all cancer tissue with a border of healthy tissue) during transurethral resection. This creates conditions for chemotherapy to address recurrence rather than treat established disease.
Treatment adherence impacts outcomes. Missed sessions or shortened dwell times reduce cumulative drug exposure. They may allow resistant cells to survive. Patients who complete their full prescribed course may demonstrate different recurrence-free intervals than those with interrupted treatment.
Comparing Intravesical Therapies
Chemotherapy and immunotherapy with BCG (Bacillus Calmette-Guérin, a weakened form of bacteria used to stimulate the immune system) represent the two main intravesical approaches. Each suits different clinical scenarios. Chemotherapy works through direct cytotoxic action (directly killing cancer cells). BCG stimulates the immune system to attack cancer cells.
For low-risk and some intermediate-risk tumours, chemotherapy may provide protection, with side effects different from those of BCG. Patients may respond differently to chemotherapy, with varying rates of treatment discontinuation due to side effects.
High-risk non-muscle-invasive bladder cancer generally warrants consideration of BCG as first-line therapy due to its ability to address progression to muscle-invasive disease (cancer that grows into the bladder’s muscle layer). However, chemotherapy serves roles when BCG fails, when BCG is unavailable, or when patients cannot tolerate immunotherapy due to immune-compromising conditions.
Lifestyle Considerations During Treatment
Hydration practices before treatment can affect drug concentration. Limit fluid intake for several hours before instillation to ensure the chemotherapy isn’t diluted by rapidly accumulating urine. However, increase fluids after treatment to help flush residual medication and soothe irritated bladder tissue.
Sexual activity requires consideration during treatment courses. Urologists generally recommend avoiding intercourse for a period after instillation. Male patients should use barrier protection (such as condoms) for several days post-treatment to prevent partner exposure to any residual medication. Female patients should discuss specific precautions with their treatment team.
Work and travel schedules may need to be adjusted around treatment days. While most patients manage daily activities during their courses, the treatment itself takes several hours, including travel and procedure time. Plan essential meetings or travel for non-treatment days to prevent scheduling conflicts and allow rest if needed.
✅ Quick Tip
Empty your bladder completely before leaving the clinic and avoid long drives home immediately after treatment—bladder irritation combined with the need to retain medication can make travel uncomfortable.
Monitoring After Treatment
Surveillance cystoscopy (a procedure where the doctor examines the inside of your bladder using a thin tube with a camera) is recommended regardless of intravesical therapy. Regular bladder examinations can detect recurrences early when they’re most treatable. Initial follow-up typically occurs at intervals, with the intervals extended if examinations remain clear.
Urine cytology (a test that examines urine for abnormal cells) complements cystoscopy by detecting cancer cells shed into urine. This diagnostic test is valuable for identifying flat, high-grade lesions (abnormal tissue patches) that may be missed during cystoscopy. The combination of both tests provides comprehensive surveillance.
Imaging studies, such as CT scans, including CT urography, may be recommended periodically to examine the upper urinary tract (the kidneys and ureters). While intravesical therapy treats the bladder, the entire urothelial lining from the kidneys to the urethra shares cancer risk. Upper tract surveillance helps detect early disease developing outside the bladder.
When to Seek Professional Help
- Fever above 38°C within a short period of treatment
- Inability to urinate for more than several hours
- Severe abdominal or pelvic pain not relieved by standard pain medication
- Heavy bleeding with clots that obstruct urination
- Rash spreading beyond the genital area
- Persistent symptoms that worsen rather than improve between treatments
Commonly Asked Questions
How long does each treatment session take?
The installation procedure takes a short time. You’ll then retain the medication for one to two hours before voiding. Including check-in, preparation, and post-treatment monitoring, plan for several hours per visit.
Can I drive myself to appointments?
Most patients safely drive themselves to and from intravesical chemotherapy sessions. Unlike systemic chemotherapy (chemotherapy delivered through the bloodstream to the whole body), intravesical treatment doesn’t typically cause drowsiness, nausea, or cognitive effects that would impair driving. However, if bladder irritation makes sitting uncomfortable, arrange alternative transport.
Will I need time off work during treatment?
Many patients continue working throughout their treatment courses, scheduling sessions around work commitments. Treatment days may require flexibility if post-procedure symptoms are bothersome. Desk work is typically manageable. Physically demanding jobs may benefit from light duties on treatment days.
What happens if I can’t hold the medication for the whole time?
Shorter retention times reduce treatment effectiveness but don’t eliminate the benefit entirely. Inform your urologist if retention proves difficult. Strategies such as adjusted volumes, anticholinergic medications (drugs that help control bladder spasms), or modified timing may help. Consistent partial retention is preferable to cancelled treatments.
Is intravesical chemotherapy painful?
Catheter insertion causes temporary discomfort rather than pain. Some patients experience cramping or urgency while retaining the medication. Post-treatment urination may burn temporarily. Everyone experiences symptoms differently, and many patients see them improve as treatment progresses.
Next Steps
Treatment success depends on completing prescribed courses, attending surveillance appointments, and promptly reporting concerning symptoms. Complete tumour resection combined with appropriate chemotherapy protocols offers the opportunity to prevent recurrence.
If you’re experiencing bladder cancer recurrence, blood in the urine, or have been diagnosed with non-muscle-invasive bladder cancer, consult with a urologist to evaluate whether intravesical chemotherapy is appropriate for your situation.
